176results about How to "Increase transcription" patented technology

Provided are retroviral vector genomes and vector systems comprising the genomes. In particular, a retroviral vector genome comprising two or more NOIs, operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and, optionally, Aromatic Amino Acid Dopa Decarboxylase are provided.

Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a transcription factor or a translation factor or a transcription factor and a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector, or at different loci. The second nucleic acid molecule can encode: one transcription factor or more than one transcription factor; or one translation factor or more than one translation factor; or at least one transcription factor and at least one translation factor. The transcription factor can be from vaccinia H4L, D6, A7, G8R, A1L, A2L, H5R, or combinations thereof. The translation factor can be from a K3L open reading frame, an E3L open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an attenuated poxvirus, e.g., NYVAC, or ALVAC.

The present invention relates to retroviral vector genomes and to vector systems comprising such genomes. In particular the present invention relates to a retroviral vector genome comprising two or more NOIs operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and optionally Aromatic Amino Acid Dopa Decarboxylase.

Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating the oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and / or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α,25-dihydroxyvitamin D2 or a pharmaceutical composition that includes such an analog to a subject in need thereof. The analog may be a 19-nor vitamin D analog such as a compound of formula IA, a compound of formula IB, or a mixture thereof where the variables R1, R2, and R3 have the values described herein.

Methods and systems for performing continuous amplification of RNA and other nucleic acids are provided. Expression profiling using the continuous flow RNA amplification systems are also provided.

New sub-monomer synthetic methods for the preparation of peptide nucleic acid oligomeric structures are disclosed that provide for the synthesis of both predefined sequence peptide nucleic acid oligomers as well as random sequence peptide nucleic acid oligomers. Further these methods also provide for the incorporation of peptide nucleic acid units or strings of such units with amino acids or strings of amino acids in chimeric peptide nucleic acid-amino acid compounds. Further disclosed are methods of making random libraries of peptide nucleic acids using the fully preformed monomers.

If the surface of metallic mold should not be highly transcribed to the surface of product in injection molding the plastic products, the transcription defects such as weld, shrinkage, etc. are caused to the surface of product. Further, if the resin should be exposed to the surface of high temperature metallic mold more than necessary during the molding, the filler and the like of glass and so forth are contained into the resin, and in this case, they are left over on the surface of metallic mold, resulting in the transcription defect. These problems can be solved by heating the surface temperature of metallic mold higher than the glass transfer temperature of resin if the resin is non-crystal and higher than the fusion point temperature if the resin crystal, with the temperature raising speed of more than 2° C. every second, maintaining this temperature during the resin charging, and by cooling at the lowering speed of more than 2° C. every second after the completion of charging. This temperature control shall be conducted with the feed back control while detecting the surface temperature of metallic mold by the temperature detection sensor mounted at the position close to the surface of metallic mold.

This invention relates to the biocatalysts for the efficient production of succinic acid and / or other products from renewable biological feedstocks. The biocatalysts have a very high efficiency for the growth-coupled production of succinic acid and / or other products from carbohydrate feed stocks as a result of both genetic manipulations and metabolic evolution. More specifically, certain biocatalysts of the present invention produce succinic acid at high titers and yield in mineral salts media during simple pH-controlled, batch fermentation without the addition of any exogenous genetic material. The genetic manipulations of the present invention are concerned with the energy-conserving strategies coupled with the elimination of alternative routes for NADH oxidation other than the routes for succinic acid production. The biocatalysts contain glucose-repressed gluconeogenic phosphoenol pyruvate carboxykinase (pck) depressed by genetic modifications and a genetically-inactivated phosphotransferase system. In terms of succinic acid production efficiency, the biocatalysts of the present invention are functionally equivalent to succinate producing rumen bacteria such as Actinobacillus succinogens and Mannheimia succiniproducens with one difference that the biocatalysts are able to achieve this high level of succinic acid production in a minimal salt medium with carbohydrate source as opposed to the requirement for a rich media for succinic acid production by rumen bacteria.

The present application describes a method for inducing or maintaining pluripotency in a cell by contacting the cell with a biological or chemical species that increases MUC1* activity.

The invention relates to retroviral vectors, especially to self-inactivating (SIN) gammaretroviral or lentiviral vectors, suitable for producing viral particles at high titers, which can be used for efficient gene transfer into mammalian cells, organs or organisms, e.g. for gene therapy. More specifically, the present invention provides modified 5′-promoter elements in the U3-region of the 5′-LTR of the vector plasmid and 3′-SIN elements modified in the U3-region of the 3′-LTR of the vector plasmid suitable for being comprised in retroviral vectors. It is a specific advantage of both the modified 5′-promoter element and of the modified 3′-SIN element, which are preferably contained in retroviral vectors in combination with one another, to increase both the titer of viral particles as well as to increase the expression of a transgene in recipient cells, which transgene is arranged between the modified LTRs according to the invention.

The present invention provides a method for treating diseases caused by either an excess or diminution of Vitamin D3. It provides pharmaceutical compositions for the treatment of such diseases and the methods by which these compositions are to be used. Also provided are methods for testing the activity of both 24(OH)ase and CCAATT / Enhancer Binding Protein β (C / EBPβ), as well as, for testing the effect of a compound on 24(OH)ase and C / EBPB activity activity. In particular embodiments, a method is provided for reducing the risk of hypercalcemia when administering 1,25(OH)2D3 or its analogs for the treatment of vitamin D diseases. Methods for both enhancing and diminishing 24(OH)ase activity are also provided.

This invention is intended to isolate and identify a vWF-specific cleaving protease.The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val, and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.

The invention provides a vector encoding a derivative of EBNA-1 that is not cytotoxic when expressed efficiently in cells, which supports extrachromosomal replication, maintenance and transcription from extrachromosomal oriP containing vectors but does not substantially activate transcription from host cell genes. Also provided is a vector having oriP and encoding a derivative of EBNA-1. The vectors of the invention may be employed in vitro and in gene therapy.

The present invention relates to the implementation of minute patterns and thus improving pattern resolution and transcription property. Provided is a printing substrate for a liquid crystal display comprising a transparent insulating substrate, and a material layer for dry etching formed on an upper surface of the transparent insulating substrate, the material layer for dry etching constituting a printing pattern, and a manufacturing method of a printing substrate for a liquid crystal display comprising forming a material layer on a transparent insulating substrate, applying a photo resist along a printing pattern on the upper side of the material layer, dry-etching the material layer along the printing pattern using the photo resist as an etching mask, and striping the photo resist.

The invention as described herein relates to the efficient production of recombinant, clinically effective lysosomal enzymes using a transformed insect cell expression system. For example, to create the expression system of the invention, any insect cell can be transfected with a plasmid comprised of a gene encoding the human glucocerebrosidase gene and genetic elements that enhance its expression. The insect cell transfected with the plasmid encoding glucocerebrosidase secretes synthesized glucocere-brosidase into its growth media. The recombinantly produced clinically effective glucocerebrosidase produced by the insect cell expression system can be used to treat Gaucher's disease.

A vector expressing two foreign genes by using RRE sequence and controlling the ratio of the expression doses of these genes owing to the modification is provided. This vector, which can be provided as a lentivirus vector based on SIVagm, is constructed by modifying a virus-origin expression regulatory sequence into another expression regulatory sequence so as to eliminate the dependency on the virus-origin protein. Although this vector has a packaging signal, it has been modified so that the risk of the occurrence of wild strains due to gene recombination is lowered and no virus structural protein is expressed. This vector is highly useful as a gene therapeutic vector with a need for transferring two genes while controlling the expression doses or expression dose ration thereof.

There is provided the use of a vector system comprising at least part of a rabies g protein, to transduce a TH positive neuron. There is also provided the use of a rabies G vector system to transduce a target site, in which the vector system travels to the target site by retrograde transport, which may comprise the step of administration of the vector system to an administration site which is distant from the target site.

The invention provides a method for producing at least one polypeptide of interest in a eukaryotic cell, the method comprising: providing a eukaryotic cell comprising nucleic acid encoding the polypeptide of interest; culturing the cell in a suitable medium; and harvesting the at least one polypeptide of interest from the eukaryotic cell, from the suitable medium, or from both the eukaryotic cell and the suitable medium, wherein the eukaryotic cell is a permanent amniocytic cell comprising a nucleic acid sequence encoding adenoviral E1A and E1B proteins. The invention also provides a eukaryotic cell comprising nucleic acid encoding a polypeptide of interest under control of a heterologous promoter, the eukaryotic cell not comprising a structural adenoviral protein, wherein the eukaryotic cell is a permanent amniotic cell comprising a nucleic acid sequence encoding adenoviral E1A and E1B proteins.

The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of interest. The present invention provides expression vectors which contain multiple copies of a transcription unit encoding a polypeptide of interest separated by at least one selective marker gene and methods for sequentially transforming or transfecting host cells with expression vectors to increase transcription unit dosage and expression.

A process for high-flux screening, capturing and separation of target moleculae from complex substance (Chinese medicine or chemical mixer) includes preparing a ds DNA microarray chip to make its probe have a binding sites of dsDNA bindin, measuring the affinity of the sites, creating the standard affinity parameter system, mixing the microarray chip with said complex substance, reacting, detecting the affinity variation, screening the varied targets, linking them to the surface of chromatographic column, filling the complex substance in it, capturing the effective moleculae by probes, eluting and collecting the effective moleculae.

The present invention relates to polynucleotides encoding adult plant pathogen resistance proteins. Also provided are transgenic plants expressing these polynucleotides to enhance the resistance of the plants to pathogens.

The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a target cell surface protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which modulate the bioactivity of the cellular proteins. The subject assays are particularly amenable for high throughput formats and are particular useful in identifying modulators of a mammalian metabotropic glutamate receptor protein.